dipsy-do dipsy-do n.—Gloss: another way of saying “an up and down (motion or change).” Note: The Dictionary of American Regional English has a similar term, “dipsy-doodle”, which is defined as dip in the road, or a “thank-you-ma’am.” «Since he started as a realtor in 1971, Love has weathered the highs and lows (or, as he calls them, “dipsy-dos”) of Burnaby’s housing market.» —“Realtor sells bungalow five times” by Brooke Larsen Burnaby Now (Canada) Oct. 3, 2007. (source: Double-Tongued Dictionary)
Yeah I know you are lol.... That was purely a short term call (like a few hours) based on the chart and the market in general. I hope it goes to $20 for ya. But....... Stoney! Savant's are gonna savant. I don't know how I do it... but you should just take notes. $11.25 close, $11.15 after hours. Ok, so... your homework tonight is to work on your overall market intuition in general, and chart reading in particular. That's your homework. but you gave it to us at $60 plus! Plus it was at this level almost when you posted it. Did you not wake up before the bell?! "We're.... offfff to see the Wizard.... " 1.9M in volume and up 3% on no news. A one month old shelf offering????? Ahhhh..... no. I have no idea. I thought perhaps you'd dig into the pipeline and see what the deal is. Yeah I know.... if it ain't on SA, Stoney is lost. Go do your homework now. -le Savante
Up 1.5% on 50% above average volume. Stoney!... this is called savanting on a red tape. It only counts when you do it before the market opens, not when a stock is already up 18%!
BOOM! Ocugen, Inc. (OCGN) NasdaqCM - NasdaqCM Real Time Price. Currency in USD Add to watchlist Visitors trend2W10W9M 7.69+0.62 (+8.77%) At close: 4:00PM EDT 8.30 +0.61 (+7.93%) After hours: 07:09PM EDT
Captain O I'd like to carve out a special section of the Garden for your input your header will be - Don't doubt the smoking fish.
GET READY!!!! TuSimple named catalyst driven idea at Morgan Stanley ahead of CFIUS update 07:27 TSP, SINA CFIUS update?????
--Fastenal says higher unit sales driven by strong growth in demand 07:26 FAST --Cytokinetics price target raised to $57 from $48 at Cantor Fitzgerald 07:22 CYTK --Blair starts Ginkgo at Outperform on 'significant' competitive advantage 07:06 DNA --Bicycle Therapeutics announces offering of $125M of American Depositary Shares 07:06 BCYC Bicycle Therapeutics announced that it has commenced an underwritten public offering of $125M of American Depositary Shares, each representing one ordinary share. All of the ADSs in the proposed offering will be sold by Bicycle. In connection with the offering, Bicycle intends to grant the underwriters in the offering a 30-day option to purchase up to an additional $18,750,000 of ADSs. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the proposed offering may be completed, or as to the actual size or terms of the offering. Bicycle plans to use the net proceeds from the offering to advance its proprietary product pipeline and for other research and development, as well as for general corporate purposes. Goldman Sachs & Co., Morgan Stanley and SVB Leerink are acting as joint book-running managers for the proposed offering. JMP Securities is acting as co-manager for the proposed offering. PUT MGM IN IRA'S***********
--Airbnb upgraded to Outperform from Market Perform at Cowen 07:00 ABNB Cowen analyst Kevin Kopelman upgraded Airbnb to Outperform from Market Perform. --Avantor reports preliminary Q3 revenue $1.83B, consensus $1.82B 06:51 AVTR "Our third quarter revenue results reflect the ongoing strength in our business," said Michael Stubblefield, president and CEO of Avantor. "We are looking forward to sharing our full financial results on our third quarter earnings release call scheduled for October 29, 2021, and to closing the Masterflex transaction in the fourth quarter." --AZZ Inc. raises FY22 EPS view to $2.90-$3.20 from $2.65-$3.05, consensus $3.03 06:38 AZZ Revises FY22 revenue view… AZZ on Your Chin... No!
--Evofem announces $10M registered direct offering 06:34 EVFM --Baird downgrades Trex to Neutral on slower decking demand 06:31 TREX Baird analyst Timothy Wojs downgraded Trex Company to Neutral from Outperform with a price target of $108, down from $116. Decking channel checks suggest sell-through demand will be slower in Q3 and Q4, driven by a combination of material and labor constraints, tougher compares, inflation and seasonality, Wojs tells investors in a research note. The analyst remains bullish on "long-term industry secular drivers" and expects sell-in to exceed sell-through in the second half of the year as channel inventories are replenished. However, slower end-use sales could create a "sentiment overhang, limiting near-term stock upside," says Wojs. --aTyr Pharma initiated with an Outperform at RBC Capital 06:23 LIFE RBC --Rush Street Interactive initiated with a Buy at Roth Capital » 06:21 RSI Ocular Therapeutix price target raised to $18 from $17 at H.C. Wainwright 06:11 OCUL H.C. Wainwright analyst Yi Chen raised the firm's price target on Ocular Therapeutix to $18 from $17 and reiterates a Buy rating on the shares after the FDA approved Dextenza for the treatment of ocular itching associated with allergic conjunctivitis. The label expansion provides the first in-office indication for the company, Chen tells investors in a research note.